Yunli Xu, Kun Wang, Yao Wu, Xuwen Da, Lingqing Yang, Yishan Yao, Xuesong Wang, Qianxiong Zhou
{"title":"A Donor–Donor-π-Acceptor–Acceptor Type Photosensitizer for Efficient Photo-Inactivation of Pathogens Within Biofilms and Host Cells","authors":"Yunli Xu, Kun Wang, Yao Wu, Xuwen Da, Lingqing Yang, Yishan Yao, Xuesong Wang, Qianxiong Zhou","doi":"10.1002/cmdc.202500703","DOIUrl":null,"url":null,"abstract":"<p>Antibacterial photodynamic therapy (aPDT) is a promising strategy for combating prevalent antibiotic-resistant bacteria. However, development of efficient aPDT agents that can simultaneously eradicate resistant pathogens within biofilms and host cells with good biocompatibility remains a big challenge. Herein, three novel D–D-<i>π</i>-A–A type dyes (TPATA, TPATC, and TPATPy) were designed and synthesized. TPATPy can efficiently produce reactive oxygen species (ROS) mainly through type I mechanism, which is beneficial for overcoming hypoxia within biofilms. Besides, introduction of pyridinium cations in TPATPy enhances the binding ability with negatively charged bacteria and biofilms through electrostatic interactions. Therefore, TPATPy not only exhibited excellent aPDT activity toward planktonic bacteria, but also destroyed mature biofilms and the embedded pathogens. Moreover, TPATPy could selectively and efficiently photo-inactivate intracellular methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), being more potent than vancomycin. So far as we know, TPATPy should be the first example that can simultaneously eradicate intractable pathogens within biofilms and host cells. The efficacy and safety of TPATPy in accelerating wound healing have also been demonstrated in an MRSA-infected skin wound model in mice. These results may provide new ideas for developing multifunctional aPDT agents to solve the intractable problems in antibacterial treatment.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 3","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202500703","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Antibacterial photodynamic therapy (aPDT) is a promising strategy for combating prevalent antibiotic-resistant bacteria. However, development of efficient aPDT agents that can simultaneously eradicate resistant pathogens within biofilms and host cells with good biocompatibility remains a big challenge. Herein, three novel D–D-π-A–A type dyes (TPATA, TPATC, and TPATPy) were designed and synthesized. TPATPy can efficiently produce reactive oxygen species (ROS) mainly through type I mechanism, which is beneficial for overcoming hypoxia within biofilms. Besides, introduction of pyridinium cations in TPATPy enhances the binding ability with negatively charged bacteria and biofilms through electrostatic interactions. Therefore, TPATPy not only exhibited excellent aPDT activity toward planktonic bacteria, but also destroyed mature biofilms and the embedded pathogens. Moreover, TPATPy could selectively and efficiently photo-inactivate intracellular methicillin-resistant Staphylococcus aureus (MRSA), being more potent than vancomycin. So far as we know, TPATPy should be the first example that can simultaneously eradicate intractable pathogens within biofilms and host cells. The efficacy and safety of TPATPy in accelerating wound healing have also been demonstrated in an MRSA-infected skin wound model in mice. These results may provide new ideas for developing multifunctional aPDT agents to solve the intractable problems in antibacterial treatment.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.